TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report released on Friday. The firm issued a hold rating on the stock.

TherapeuticsMD Stock Performance

Shares of TXMD opened at $1.86 on Friday. The company’s 50 day simple moving average is $2.25 and its 200-day simple moving average is $2.32. TherapeuticsMD has a 12-month low of $1.86 and a 12-month high of $4.73.

Hedge Funds Weigh In On TherapeuticsMD

A hedge fund recently bought a new stake in TherapeuticsMD stock. ADAR1 Capital Management LLC purchased a new position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 272,160 shares of the company’s stock, valued at approximately $612,000. ADAR1 Capital Management LLC owned 2.57% of TherapeuticsMD as of its most recent SEC filing. 30.74% of the stock is currently owned by institutional investors and hedge funds.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.